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protein. Moreover, high MBL serum levels were associated 
with more advanced disease stage. No differences in distri-
bution of the MASP2 +359 A>G (D120G) SNP or MASP-2 
serum levels were found between cancer patients and their 
controls. However, the highest frequency of the A/G (MASP2) 
and LXA/O or O/O (MBL2) genotypes was found among OC 
patients with tumours of G1–2 grade (well/moderately differ-
entiated).Furthermore, MBL deficiency-associated genotypes 
predicted prolonged survival. None of the parameters inves-
tigated correlated with CA125 antigen or patients’ age. The 
local expression of MBL2 and MASP2 genes was higher in 
women with ovarian cancer compared with controls. It is con-
cluded that the expression of MBL and MASP-2 is altered in 
ovarian cancer, possibly indicating involvement of the lectin 
pathway of complement activation in the disease.
Keywords Ovarian cancer · Benign ovarian tumours · 
Mannose-Binding Lectin (MBL) · MASP · Complement
Abbreviations
DAMP  Danger-associated molecular pattern
MASP  Mannose-Binding Lectin-associated serine 
protease
MBL  Mannose-Binding Lectin
MDSC  Myeloid-derived suppressor cells
PAMP  Pathogen-associated molecular pattern
RNI  Reactive nitrogen species
ROI  Reactive oxygen species
SNP  Single nucleotide polymorphism
Introduction
The complement system may play a dual role in the patho-
genesis of cancer. On the one hand, it may contribute to 
Abstract Mannose-Binding Lectin (MBL) is a serum pat-
tern recognition molecule, able to activate complement in 
association with MASP proteases. Serum levels of MBL and 
MASP-2, activities of MBL–MASP complexes, single nucle-
otide polymorphisms of the MBL2 and MASP2 genes and/
or their specific mRNA expression in ovarian sections were 
investigated in 128 patients suffering from primary ovarian 
cancer (OC) and compared with 197 controls (C), encom-
passing both patients with benign ovarian tumours (n = 123) 
and others with no ovarian pathology (n = 74). MBL defi-
ciency-associated genotypes were more common among OC 
patients than among controls. The O/O group of genotypes 
was associated with ovarian cancer (OR 3.5, p = 0.02). In 
A/A homozygotes, MBL concentrations and activities were 
elevated in the OC group and correlated with C-reactive 
Electronic supplementary material The online version of this 
article (doi:10.1007/s00262-014-1579-y) contains supplementary 
material, which is available to authorized users.
A. S. Swierzko · A. Szala · A. Sokolowska · M. Cedzynski (*) 
Laboratory of Immunobiology of Infections, Institute 
of Medical Biology, Polish Academy of Sciences, Lodowa 106, 
93-232 Lodz, Poland
e-mail: mcedzynski@cbm.pan.pl
S. Sawicki · M. Sniadecki · D. Wydra 
Department of Gynaecology, Oncologic Gynaecology 
and Gynaecologic Endocrinology, Medical University of Gdansk, 
Kliniczna 1a, 80-402 Gdan´sk, Poland
J. Szemraj 
Department of Biochemistry, Medical University of Lodz, 
Mazowiecka 6/8, 92-215 Lodz, Poland
A. Kaluzynski 
Department of Clinical Pathomorphology, Polish Mother’s 
Memorial Hospital Research Institute, Rzgowska 281/289, 
93-338 Lodz, Poland
1130 Cancer Immunol Immunother (2014) 63:1129–1140
1 3
the clearance of potentially tumourigenic cells harbouring 
pathogen- or danger-associated molecular patterns (PAMPs 
or DAMPs). On the other hand, complement activity may 
favour tumour development. For example, it has been sug-
gested (based on an animal model) that myeloid-derived 
suppressor cells (MDSC), recruited in a C5a-dependent 
way, stimulate production of reactive oxygen species and 
reactive nitrogen species (ROS and RNS) and then con-
tribute to the inhibition of a CD8+ T cell-mediated anti-
tumour response [1].
Mannose-Binding Lectin (MBL) may interact directly 
with neoplastic cells (e.g. by MBL-dependent cell-medi-
ated cytotoxicity [2]), or inhibit metalloproteases that 
degrade extracellular matrix, or protect against chemo-
therapy-related infections or infections with cancerogenic 
agents (reviewed by Swierzko et al. [3]). Moreover, MBL 
may interact with antigen-presenting cells (often present 
in the tumour microenvironment), influence their activity/
proliferation and thereby contribute to the outcome of the 
anti-tumour immune response [4, 5].
The gene responsible for MBL synthesis (MBL2) is 
localized to chromosome 10 (10q11.2–q21). Single nucle-
otide polymorphisms (SNPs) in its first exon are respon-
sible for altered MBL serum concentration and impaired 
function. The dominant alleles D, B and C (collectively 
designated O), corresponding to mutations in codons 52, 
54 and 57, respectively, are associated with lower MBL 
levels compared with the A (wild-type or normal) allele. 
Polymorphisms in the promoter region (H/L and Y/X at 
positions −550 and −221, respectively) also influence 
the serum protein concentration. Homozygotes or com-
pound heterozygotes for variant alleles (O/O) as well as 
LXA/O heterozygotes are considered to be MBL deficient 
(reviewed in [3]). Although MBL is predominantly syn-
thesized in the liver, some MBL2 gene expression (at the 
mRNA level) has been found in bone marrow, fetal lung, 
small intestine and testis [6]. We ourselves have reported 
the presence of MBL protein and specific mRNA in both 
normal and malignant ovaries. Moreover, MBL protein 
was detected in ascites from women with ovarian cancer 
[7]. The transcription of the MBL2 gene is known to be 
up-regulated by IL-6, dexamethasone, heat shock, thyroid 
hormones and growth hormone while down-regulated by 
IL-1 [8, 9].
The ability of MBL to activate the complement cas-
cade results from its cooperation with MBL-associated 
serine proteases (MASPs), encoded by the MASP1/3 and 
MASP2 genes, localized to chromosomes 3 (3q27–q28) 
and 1 (1p36.2–3), respectively [10]. MASP-2 cleaves com-
plement factors C4 and C2 with high efficiency. Among 
Caucasians, one SNP (+359 A>G; D120G) leads to dimin-
ished MASP-2 activity in heterozygotes and total MASP-2 
deficiency in homozygotes. This mutation affects the struc-
ture of the CUB1 domain and abolishes interaction with 
the pattern recognition molecules of the lectin pathway of 
complement activation [11].
MASP-1 was demonstrated to associate with MASP-2 
in the same complex with MBL and to activate MASP-2 
directly. Moreover, it is able to activate factor C2, produc-
ing the majority (60 %) of C2a molecules, necessary for 
the C3 convertase. Thus, it is considered to be crucial for 
lectin pathway activation [12–14]. MASP-1 could pos-
sibly also be involved in the coagulation cascade with its 
substrates being fibrinogen, factor XIII and thrombin-acti-
vatable fibrinolysis inhibitor (TAFI). Moreover, its throm-
bin-like activity enables cleaving of protease-activated 
receptor-4, a mediator of inflammation and platelet acti-
vation (reviewed by Yongqing et al. [15] and Matsushita 
et al. [16]). Recently, Dobo et al. [17] found evidence that 
another MASP-1 substrate is high-molecular-weight kini-
nogen. This activity (like that of kallikrein) enables release 
of bradykinin, a highly pro-inflammatory mediator of the 
contact system. Although these authors noted that MASP-2 
also cleaved kininogen, no bradykinin was released. To 
date, no case of MASP-1 deficiency has been described, 
but curiously, fish and birds do well without possessing 
MASP-1 [18, 19].
The liver is the main source of both MASP-1 and 
MASP-2, but low expression at the mRNA level has also 
been found in colon, heart, lung, kidney, placenta, brain 
(for MASP-1), and in testis and small intestine (for both 
MASP-1 and MASP-2) [20]. In contrast to the MBL2 
gene, transcription of MASP1/3 and MASP2 was shown to 
be stimulated by IL-1β and abolished by IL-6. Moreover, 
MASP1/3 expression is down-regulated by IFN-γ [21].
We previously reported an association between low 
MBL-conferring haplotypes and ovarian cancer, but sur-
prisingly no corresponding relationship with serum MBL 
concentration or activity [7]. Also, MBL2 gene expression 
was detected in all ovarian tissues examined, but significant 
MASP2 expression was confined to malignant ovarian tis-
sue only. We later found elevated serum Ficolin-2 (L-fico-
lin) and Ficolin-3 (H-ficolin) in ovarian cancer patients, 
while the local expression of the corresponding genes was 
decreased [22]. In the present case-controlled, retrospective 
study, we have revisited the relationship between MBL and 
ovarian cancer with an entirely separate series of patients 
and controls in order to confirm or refute the apparent 
paradox (association with genetic MBL deficiency, but not 
serum MBL deficiency) reported earlier, and we have sup-
plemented our investigations to include MASP-2 concen-
trations, MASP2 genotyping and MBL–MASP-1 complex 
activities. Additionally, gene expression data have been 
markedly extended.




Both cancer patients and their controls attended the 
Department of Gynaecology, Oncologic Gynaecology 
and Gynaecologic Endocrinology, Medical University of 
Gdansk, Poland and were identical to the patient groups 
described in our Ficolin-2 and Ficolin-3 study [22]. A 
total of 128 women (aged 28–86 years, mean: 58.6) had 
the diagnosis of primary ovarian cancer (OC group). 
The majority of those patients suffered from serous car-
cinoma (n = 83), but twenty-five patients had ovarian 
tumours of other histological types, including endometri-
oid, mucinous and clear-cell carcinomas. Seventy-eight 
patients had advanced disease stage (FIGO stage III–IV) 
while 25 were classified as FIGO I–II. Sixty-five women 
had poorly differentiated tumours (G3), while 33 had 
well-differentiated tumours (G1–2). For some patients, 
complete clinical data were not available. Ovarian can-
cer patients were compared with two separate reference 
groups of non-cancer patients, collectively classified as 
controls (C): 123 patients diagnosed with benign tumours 
of the ovary (BT; aged 19–82 years, mean: 45.6) and 74 
patients operated on because of leiomyomas or dysfunc-
tional uterine bleeding but without pathological changes 
in the ovaries (NO group; aged 20–76 years, mean: 48.2). 
The BT group included patients with ovarian serous cysts, 
adenomas, fibromas, teratomas or endometriosis. Blood 
from all patients was taken preoperatively while tissue 
samples were taken during primary surgery. Approval of 
the local ethical committee was obtained, as was the writ-
ten informed consent of patients.
Blood, serum and ovarian tissue samples
Blood samples for DNA preparation were taken into tubes 
containing sodium citrate and stored at −20 °C. Sera were 
prepared from blood samples collected into tubes without 
anticoagulant and stored at −70 °C until testing. Tissue 
samples were collected into tubes with RNALater (Life 
Technologies, USA) and stored at −70 °C.
Determination of protein concentrations and activities
Serum MBL concentrations [23], MBL–MASP-2 com-
plex activities [23] and MASP-2 concentrations [24] were 
measured by ELISA as described previously. Murine anti-
human MBL mAbs (clone HYB 131-01; BioPorto, Den-
mark), goat polyclonal anti-human C4 Abs (Calbiochem, 
USA) and corresponding HRP-conjugated secondary anti-
bodies were used for detection of MBL and activated C4b 
fragment (for an estimation of MBL–MASP-2 complex 
activity), respectively. In the case of MASP-2 concentration 
(“sandwich ELISA”), rat anti-MASP-2 mAb (clone 8B5) 
was used for coating while biotinylated rat anti-MASP-2/
MAp19 mAb (clone 6G12) followed by Eu3+-labelled 
streptavidin (Perkin Elmer, USA)—for detection. Both 
antibodies were kindly provided by Prof. Jens C. Jense-
nius (Aarhus University, Denmark). To test MBL–MASP-1 
complex activity, the fluorescence method described by 
Presanis et al. [25] was used. Briefly, sera prediluted 1:10 
were added to mannan-coated wells of microfluor white 
plates (NUNC, Denmark). VPR-AMC peptide (Bachem, 
Switzerland) was used as the substrate for MASP-1. The 
samples were excited at 355 nm, and emission was read at 
460 nm every 30 s for 1 h, using a Varioskan Flash reader 
(Thermo Scientific, USA). Serum from a healthy volun-
teer (containing 2,000 ng MBL/ml, with YA/YA MBL2 
genotype) was used as a standard (MBL–MASP-1 complex 
activity in this serum was arbitrarily assigned the value of 
1 U/ml).
In general, “low values” corresponded to below the 10th 
percentile (MASP-2 concentration) among controls or the 
detection limits (MBL–MASP-1 and MBL–MASP-2 activ-
ities) and “high values” to above the 90th percentile among 
controls (chosen arbitrarily). An exception was made for 
MBL (10th percentile: 55 ng/ml) deficiency, as the value of 
100 ng/ml appears to be widely accepted [26, 27]. Conse-
quently, a cut-off for “high MBL” (3,000 ng/ml) exceeded 
the 90th percentile (1,998 ng/ml) within the control group. 
Detection limits were as follows: 10 ng/ml (MBL con-
centration), 25 ng/ml (MASP-2 concentration), 60 mU/ml 
(MBL–MASP-2 activity); and 50 mU/ml (MBL–MASP-1 
activity). Values below those mentioned above were dis-
played as “1” in logarithmic-scale graphs.
Investigation of single nucleotide polymorphisms of the 
MBL2 and MASP2 genes
DNA was extracted from blood samples with the use of 
GeneMATRIX Quick Blood Purification Kit (EURx Ltd, 
Poland), according to the manufacturer’s protocol. Single 
nucleotide polymorphisms of the MBL2 [28] and MASP2 
[24] genes were analysed as previously described. The 
MBL2 genotypes: O/O (where “O” corresponds to B, C 
or D exon 1 mutations) and LXA/O (where “L” and “X” 
correspond to the promoter variants at positions −550 and 
−221, respectively while “A” to wild-type exon 1) were 
considered to define MBL deficiency.
Determination of MBL2 and MASP2 gene expression using 
real-time PCR method
The MBL2 and MASP2 gene expression levels were investi-
gated essentially as previously described [7]. PCR primers 
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specific for TATA-box protein (TBP, used as a housekeep-
ing gene) were as described by Li et al. [29].
Analyses were performed with ABI Prism 7700 (SDS 
Software). Results were normalized to values obtained 
for TBP. Relative gene expression levels were obtained 
using the ΔΔCt method [30]. Specificity of amplifica-
tion was further confirmed by obtaining melting curve 
profiles.
Statistical analysis
The Statistica (version 10, StatSoft Poland) software pack-
age was used for data management and statistical calcula-
tions. Median serum MBL and MASP-2 concentrations, 
activities of MASP-1 and MASP-2, complexed with MBL 
as well as MBL2 and MASP2 gene expressions in ovarian 
sections were compared by the Mann–Whitney U test. Cor-
relations were determined by Spearman’s test. The frequen-
cies of MBL2 and MASP2 gene variants were compared by 
Fisher’s exact test (two-sided). Odds ratios were obtained 
with the use of MediCalc software (http://www.medcalc.
org).
Deviations of the observed genotype frequencies from 
Hardy–Weinberg equilibrium were calculated separately 
for the C and OC groups. An exact test was applied, due 
to the low frequency of certain gene variants [31]. For the 
MBL2 gene, data for each exon 1 SNP were calculated sep-
arately (D, B and C). The 36-month survival was calculated 
using the Kaplan–Meier method, and the groups were com-
pared with the use of a log-rank test. P values <0.05 were 
considered statistically significant.
Results
Polymorphisms of MBL2 and MASP2 genes
Variant alleles of the MBL2 structural gene were found in 
46 (39 %) of 117 OC patients and in 60 (35 %) of 172 con-
trols. Within the C group, these variants were commoner 
among women with benign ovarian tumours (Table 1). 
However, O/O genotypes were significantly more frequent 
in OC patients than in controls (9.4 vs 2.9 %, p = 0.03; 
Table 1) and associated with an increased probability of 
developing ovarian cancer (OR 3.5; p = 0.02). Taking into 
account promoter polymorphisms, the higher frequency 
of MBL deficiency-associated genotypes (LXA/O + O/O) 
among OC patients (18.8 vs 11.7 %; OR 1.8; p = 0.09 
when compared with C group) reflected a difference from 
the NO reference group alone (18.8 vs 6.2 %; OR 3.5; 
p = 0.03) (Table 1). Frequencies of A (wild-type), B, C and 
D alleles in each group are given in Supplementary Table 1. 
The D allele (codon 52 mutation) was more frequent in 
both tumour (BT and OC) groups relative to the NO group. 
No significant deviation from Hardy–Weinberg equilibrium 
was found for polymorphisms at codons 52 (A/D), 54 (A/B) 
or 57 (A/C) (p > 0.05).
No variant homozygote for +359 A>G (D120G) MASP2 
gene polymorphism was found. Although a trend towards 
higher frequency of heterozygosity in the OC group was 
observed (Table 1), the differences in comparison with C, 
NO or BT groups did not reach statistical significance. No 
significant deviation from Hardy–Weinberg equilibrium 
was observed (p > 0.05).
Table 1  Frequency of MBL2 (a) and MASP2 (b) genotypes in ovarian cancer patients and controls
C, control group, including NO, patients with no ovarian pathology and BT, patients with benign ovarian tumours; OC, patients with primary 
ovarian cancer
a
 p = 0.03; OR 3.5 (vs C)
b
 p = 0.03; OR 3.5 (vs NO)
MBL2 gene Group (n)
C (172) NO (65) BT (107) OC (117)
(a)
 A/A 65.1 69.2 62.6 60.7
 YA/O 23.3 24.6 22.4 20.5
 XA/O 8.7 4.6 11.2 9.4
 O/O 2.9 1.5 3.7 9.4a
 XA/O + O/O 11.6 6.2 15 18.8b
MASP2 gene Group (n)
C (174) NO (67) BT (107) OC (117)
(b)
 A/A 91.4 92.5 90.7 87.2
 A/G 8.6 7.5 9.3 12.8
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Interestingly, the frequencies of both MBL deficiency-asso-
ciated genotypes (LXA/O + O/O) and MASP2 A/G heterozy-
gosity were highest among patients with well-/moderately 
differentiated tumours (G1–2 grade) (Table 2). Analysis of 
survival of OC patients (n = 79) performed three years after 
surgery revealed better survival of carriers of MBL2 LXA/O 
or O/O (n = 15) compared with A/A or YA/O genotypes (log-
rank test: p = 0.03; Fig. 1a). For MASP2 gene, the correspond-
ing trend did not quite reach statistical significance (p = 0.06, 
Fig. 1b). Nevertheless, 10 out of 51 patients who survived 
≥36 months carried the D120G mutation (compared with 
1/28 of those patients who died within 3 years after operation).
Serum MBL and MASP-2 concentrations
The median serum MBL in the OC patients (714 ng/ml) 
did not differ significantly from that of the control group 
(641 ng/ml) (full details are presented in Supplemen-
tary Table 2) However, MBL2 A/A homozygotes suffering 
from ovarian cancer had generally higher MBL concentra-
tions (median 1,692 ng/ml) than their counterparts in the 
C (1,231 ng/ml), NO (1,054 ng/ml) or BT (1,301 ng/ml) 
groups (Fig. 2a). Moreover, the highest (>3,000 ng/ml) 
MBL levels were significantly commoner in OC than in any 
of the reference groups while no difference in the frequency 
of the lowest MBL levels (<100 ng/ml) was found (Table 3).
Histological grading was known for 13 patients with 
very high (>3,000 ng/ml) serum MBL: 12 were G3 (OR 
7.3; p = 0.05, vs G1–2 patients). Fifteen very high serum 
MBL patients were FIGO staged: 13 were grades III or IV 
(OR 2.1; p = 0.5 vs FIGO I–II patients).
In general, MASP-2 concentrations did not differ 
between the groups (Supplementary Table 2), even when 
MASP2 genotype was taken into account (Fig. 2b). Fur-
thermore, the frequencies of extreme levels (<191 ng/ml or 
>627 ng/ml) were much the same (Table 3).
MBL concentrations correlated inversely with MASP-2 
levels in the control patients (R = −0.24; p = 0.002) but 
not in the OC group. MBL levels weakly correlated with 
CRP within the OC group only (R = 0.3, p < 0.05). No cor-
relations with CA125 antigen concentration or patients’ age 
were noted (not shown).
Activities of MBL–MASP complexes
Median MBL–MASP-1 (173 mU/ml) and MBL–MASP-2 
(233 mU/ml) activities in the OC patients did not differ sig-
nificantly from those of their controls (202 and 224 mU/
ml, respectively) (Supplementary Table 2), even in MBL2 
A/A homozygotes (Fig. 2c, d). However, when patients 
carrying both MBL2 A/A and MASP2 A/A genotypes were 
compared, MBL–MASP-2 activity was highest in the OC 
group (p < 0.05 compared with the C group) (Supplemen-
tary Table 3).
Similarly, high values for MBL–MASP-2 activity were 
commoner in the OC than in the C patients (p < 0.05), but 
the corresponding trend for MBL–MASP-1 activity did 
not achieve statistical significance (Table 3). Frequencies 
of functional MBL–MASP-2 relative deficiency (activ-
ity <60 mU/ml) did not differ between the groups, but 
MBL–MASP-1 deficiency (<50 mU/ml) was more com-
mon in OC compared with the NO group (p = 0.035) 
(Table 3).
As expected, highly significant correlations between 
serum MBL and MBL–MASP-1 activity (0.88 ≤ R ≤ 0.91) 
and between serum MBL and MBL–MASP-2 activity 
(0.73 ≤ R ≤ 0.85) were noted in all groups. None of the 
parameters investigated correlated with CA125 or patients’ 
age (not shown).
MBL and MASP-2-specific mRNA expression in ovarian 
sections
Expression of both MBL2 and MASP2 genes, at the 
mRNA level, was detected in all ovarian sections tested 
from OC patients (n = 64) and controls (n = 103). 
Table 2  Frequency of MBL deficiency-associated genotypes and MASP2 A/G heterozygosity
C, control group, including NO, patients with no ovarian pathology and BT, patients with benign ovarian tumours; OC, patients with primary 
ovarian cancer
a
 Numbers of samples tested for D120G MASP2 polymorphism
b
 p = 0.05 (vs OC G3); p = 0.01 (vs C); p = 0.04 (vs NO); p = 0.07 (vs BT)
c
 p = 0.06 (vs OC G3); p = 0.02 (vs C); p = 0.03 (vs NO); p = 0.04 (vs BT)
d
 p = 0.01 (vs OC G3); p = 0.002 (vs C); p = 0.01 (vs NO); p = 0.01 (vs BT)
Group C NO BT OC G1-2 OC G3
n 172 (174)a 65 (67)a 107 33 63
MBL deficiency-associated genotypes (LXA/O + O/O) (%) 11.6 6.2 15 30.3b 12.7
MASP2 A/G heterozygotes (%) 8.6 7.5 9.3 24.2c 7.9
LXA/O + O/O (MBL2) and A/G (MASP2) (%) 0.6 0 0.9 12.1d 0
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Median values were significantly higher in OC patients 
compared with their controls (Fig. 3a, b). For the MASP2 
gene, data from malignant tumours differed signifi-
cantly from those from benign tumours or normal ova-
ries (Fig. 3b), but the average relative expression of 
the MBL2 gene did not differ between the OC and NO 
groups (Fig. 3a).
The expression levels of MBL2 and MASP2 genes were 
found to correlate with each other in all groups. Local 
MBL2 expression correlated significantly with serum 
MBL level in controls but not in OC patients. No associa-
tion between MASP-2-specific mRNA and serum MASP-2 
concentration was observed. Moreover, neither MBL2 nor 
MASP2 expression level correlated with CA125 antigen or 
age of patients (not shown).
Discussion
Various disorders (endometriosis, pelvic inflammatory dis-
ease, etc.) are postulated to increase the risk for epithelial 
ovarian cancer (reviewed by Maccio and Madeddu [32]). 
MBL, by participating in the clearance of microorganisms, 
might help to limit inflammation in the reproductive sys-
tem. As mentioned, it may also interact directly with cer-
tain cancer cells or inhibit extracellular matrix-degrading 
Fig. 1  Kaplan–Meier plot of 
MBL2 (a) and MASP2 (b) geno-
types and survival in patients 
with ovarian cancer
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enzymes. The results reported here broadly confirm our 
previous finding (from another cohort) [7] that MBL 
deficiency-associated genotypes are over-represented in 
ovarian cancer. In contrast to the earlier study, controls 
(previously defined as “healthy women with no history of 
cancer”) were recruited on the basis of histopathological 
examination enabling us to distinguish between patients 
with benign ovarian tumours and those without any ovarian 
pathology. The MBL2 relationship was stronger in compar-
ison with the latter group. Recently, Nevadunsky et al. [33] 
have also postulated that the MBL2 gene B variant may be a 
risk factor for ovarian cancer. Several reports demonstrated 
the significance of MBL2 gene SNPs in gastric [34, 35], 
hepatic [36] or colon cancers [37], glioma [38] and acute 
Fig. 2  a Individual MBL 
serum concentrations, depend-
ing on MBL2 genotypes; b 
individual MASP-2 serum 
concentrations, depending on 
MASP2 genotypes; c individual 
MBL–MASP-2 serum activities, 
depending on MBL2 genotypes; 
d individual MBL–MASP-1 
serum activities, depending on 
MBL2 genotypes. C, combined 
control group; NO, women with 
normal ovaries; BT, patients 
with benign ovarian tumours; 
OC, patients with primary 
ovarian cancer. Values below 
the detection limit are presented 
as “1”. Bars indicate median 
values (presented by numbers 
below corresponding geno-
types). When the majority of 
values were under the detection 
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lymphoblastic leukaemia [39]. In contrast, Ytting et al. [40] 
found no such association with colorectal cancer.
We also confirmed the absence of association of serum 
MBL activities (both binding to mannan and comple-
ment-activating ability) and ovarian cancer. Indeed, OC 
patients with normal (wild-type) genotypes had higher 
levels of serum MBL than their controls. This is likely 
to be a nonspecific response to an inflammatory stimulus 
and accounts for the correlation with C-reactive protein. 
Earlier, elevated MBL concentrations in patients with 
papillary thyroid carcinoma (compared with subjects with 
thyroid adenoma and healthy controls) were reported. 
However, MBL2 polymorphisms were not analysed in that 
study [41].
The reason for an association with genetically defined 
MBL deficiency but not serum protein deficiency is not 
obvious. One possibility is the existence of a cancer sus-
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MBL2 alleles, which can account for a number of incon-
sistent findings in the context of MBL and various malig-
nant and non-malignant diseases (discussed by Kilpatrick 
[26]). Alternatively, this putative linked gene may act as 
a disease modifier, accounting for the prediction of longer 
survival by MBL deficiency-associated (LXA/O, O/O) 
genotypes. Conversely, the association between very 
high serum MBL and poor prognostic indicators (grade 
3 tumours and FIGO stage III-IV) is consistent with this 
view as all the very high serum MBL patients had wild-
type genotypes.
Neither MASP-2 serum concentration nor the +359 
A>G polymorphism of its gene was associated with ovar-
ian cancer. The former correlated with Ficolin-3 levels 
(reported previously by Szala et al. [22]), within both OC 
and C groups (not shown). Earlier, Ytting et al. [42, 43] 
reported high MASP-2 serum level to be a biomarker pre-
dicting recurrence and poor survival of patients with 
colorectal cancer. That was not associated with MASP2 
polymorphism [40]. Moreover, elevated MASP-2 levels in 
children with tumours of the central nervous system [44] 
and in patients with papillary thyroid carcinoma [41] have 
been reported.
An important novel aspect of this study was investiga-
tion of local MBL2 and MASP2 expression, at the mRNA 
level. The MASP2 gene relative expression was signifi-
cantly higher in malignant ovaries compared with nor-
mal organs or those affected by benign tumours. For the 
MBL2 gene, the differences were less evident, but a clear 
difference between OC and BT patients was observed. 
Interestingly, earlier, we found opposite relationships for 
Ficolin-2 and Ficolin-3 genes [22]. Consequently, relative 
expression levels of both MBL2 and MASP2 inversely cor-
related with that of FCN2 [22] in both OC and C groups 
(not shown). Recently, expression of the MBL2 gene in 
papillary thyroid carcinoma tissue specimens was shown to 
be higher than in those from adenoma or normal thyroid 
glands [45].
Since many statistical tests have been performed to com-
pare frequencies of MBL2 and MASP2 genotypes/alleles 
(MBL2 O/O, XA/O + O/O genotypes, O alleles; MASP2 
A/G heterozygosity and G alleles), protein concentrations/
activities (MBL serum levels, MBL–MASP-1 and MBL–
MASP-2 activities together with frequencies of extreme 
values) as well as relative gene expression levels (MBL2 
and MASP2), there is a real possibility that some appar-
ently “significant” findings may be due to chance (type 1 
error). However, that consideration does not apply to the 
main conclusions and the statistics underpinning them, 
because the central findings are confirmations of apparent 
relationships previously obtained. However, the other rela-
tionships indicated here for the first time cannot be consid-
ered established, but serve to formulate hypotheses, which 
may be subsequently confirmed or refuted (ideally by inde-
pendent researchers).
To summarize, our previous [7, 22] and current data 
demonstrate certain abnormalities in expression (mRNA, 
protein levels) of factors specific for the lectin pathway 
Table 3  Incidence of extreme (low or high) concentrations/activities of MBL and MASPs in ovarian cancer patients and controls
Percentages are given in parentheses
C, control group, including NO, patients with no ovarian pathology and BT, patients with benign ovarian tumours; OC, patients with primary 
ovarian cancer
a
 n = 162 for MASP-2 concentration and MBL–MASP-1 activity
b
 n = 61 for MBL–MASP-2 activity
c
 n = 100 for MASP-2 concentration and MBL–MASP-1 activity; n = 103 for MBL–MASP-2 activity
d
 n = 106 for MASP-2 concentration
e
 p = 0.0004; OR 6.5 (vs C); p = 0.001; OR 21 (vs NO); p = 0.01; OR 4 (vs BT)
f
 p < 0.05; OR 2.1(vs C)
g
 p = 0.035; OR 2.5 (vs NO)
Parameter Cut-off Frequency in groups
C (n = 164)a NO (n = 62)b BT (n = 102)c OC (n = 107)d
MBL concentration <100 ng/ml 27 (16.5) 11 (17.7) 16 (15.7) 20 (18.7)
>3,000 ng/ml 4 (2.4) 0 4 (3.9) 15 (14)e
MASP-2 concentration <191 ng/ml 14 (8.6) 6 (9.7) 8 (8) 9 (8.5)
>627 ng/ml 17 (10.5) 6 (9.7) 11 (11) 14 (13.2)
MBL–MASP-2 activity <60 mU/ml 18 (11) 4 (6.6) 14 (13.6) 18 (16.8)
>800 mU/ml 17 (10.4) 7 (11.5) 10 (9.7) 21 (19.6)f
MBL–MASP-1 activity <50 mU/ml 34 (21) 8 (12.9) 26 (26) 29 (27.1)g
>605 mU/ml 17 (10.5) 6 (9.7) 11 (11) 17 (15.9)
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of complement in ovarian cancer. This possibly indicates 
involvement in pathogenesis, although it is possible that at 
least some of these disturbances are effects of carcinogene-
sis. Genetic polymorphisms might influence both risk of dis-
ease (MBL2) and prognosis (probably MBL2 and MASP2).
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Fig. 3  Expression (at the 
mRNA level) of MBL2 (a) and 
MASP2 (b) genes in ovarian 
section samples. C, combined 
control group; NO, women with 
normal ovaries; BT, patients 
with benign ovarian tumours; 
OC, patients with primary ovar-
ian cancer. Bars indicate median 
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